Penumbra (NYSE:PEN) announced today that it received FDA clearance for its Thunderbolt thrombectomy platform for stroke.
People with mild cognitive impairment (MCI) are at higher risk of developing dementia. Indeed, many of them experience a gradual decline in cognitive performance over time. Smartphone- or tablet-based memory tests can capture this subtle decline more quickly than conventional testing. These findings come from a study by DZNE in collaboration with university hospitals in Germany, the University of Wisconsin–Madison in the United States, and the startup neotiv.
The integration of AI into digital pathology has the potential to transform cancer diagnostics by enabling scalable, quantitative analysis of tissue specimens. However, widespread deployment of AI-assisted pathology remains challenged by the need for costly imaging infrastructure and the lack of reliable mechanisms to assess prediction confidence.
A new study by investigators from Mass General Brigham Cancer Institute has found that an ultrasensitive blood test called HPV-DeepSeek could help identify which people with HPV-associated head and neck cancer still had cancer cells in their bodies after surgery and may benefit the most from additional treatments. The results are published in Science Translational Medicine.
Experts in Heidelberg, Germany, have developed an AI system that can classify brain tumors with unprecedented accuracy using standard microscopic tissue sections.
The research group led by Peng Wu at the Max Planck Institute of Molecular Physiology has now developed a new type of “molecular eraser” targeting the mRNA of the cancer protein NRAS.
Researchers at the Nuffield Department of Medicine, University of Oxford, together with Newcastle University’s Translational and Clinical Research Institute and the Department of Immunology at Cambridge University Hospitals NHS Foundation Trust, have identified an important driver of inflammatory bowel disease (IBD).
A new study in Nature by a team led by Doudna has uncovered a powerful new approach to selectively kill cancer cells using a CRISPR enzyme called Cas12a2.
Three commercially available radiology AI systems have shown the potential to flag early signs of breast cancer up to six years before a diagnosis, according to a study published in Radiology.
A lightweight wearable device developed by UNSW engineers could one day help people monitor their heart and breathing health from home, potentially reducing hospital visits and allowing doctors to detect problems earlier.